초록 ▼

Foamable compositions which exhibit reduced surface tack and better handling characteristics are obtained through the use of specific combinations of epoxy resins. One or more solid epoxy resins are utilized together with liquid and/or semi-solid epoxy resins. The compositions, which preferably cont

Foamable compositions which exhibit reduced surface tack and better handling characteristics are obtained through the use of specific combinations of epoxy resins. One or more solid epoxy resins are utilized together with liquid and/or semi-solid epoxy resins. The compositions, which preferably contain hollow glass microspheres, are capable of providing foams which are useful in the manufacture of reinforced structural members.

대표청구항 ▼

Foamable compositions which exhibit reduced surface tack and better handling characteristics are obtained through the use of specific combinations of epoxy resins. One or more solid epoxy resins are utilized together with liquid and/or semi-solid epoxy resins. The compositions, which preferably cont

Foamable compositions which exhibit reduced surface tack and better handling characteristics are obtained through the use of specific combinations of epoxy resins. One or more solid epoxy resins are utilized together with liquid and/or semi-solid epoxy resins. The compositions, which preferably contain hollow glass microspheres, are capable of providing foams which are useful in the manufacture of reinforced structural members. t of a compound of formula (Id): wherein: R1bis one or more substituents independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aralkyl, hydroxyalkenyl, alkoxyalkyl, dialkylaminoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, piperazinylalkyl, tetrazolylalkyl, and imidazolylalkyl; R3is phenyl substituted by one or more substituents independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, formyl, nitro, cyano, aminoalkoxy, alkenyl, hydroxyalkyl, amino, alkylcarbonylamino, arylcarbonylamino, alkoxycarbonylalkylcarbonylamino, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, ureido, glycinamido, tetrazolylalkyl, plperodinylalkyl, and imidazolylalkyl; R4is --O--; R5is an alkylene chain or an alkylidene chain, R6is --C(O)-- or --C(S)--; and R10is a heterocyclyl selected from the group consisting of furanyl and thienyl wherein the heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of halo and nitro; as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof. he malignancy or neoplasm. 3. A method in accordance with claim 2, wherein the hypocalcemic vitamin D compound is represented by formula II: wherein A1and A2each are hydrogen or a carbon--carbon bond, thus forming a double bond between C-22 and C-23; R1and R2are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that R1and R2cannot both be an alkenyl group, or taken together with the carbon to which they are bonded, form a C3-C8cyclocarbon ring; R3is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X1is hydrogen or hydroxyl, and X2is hydrogen or hydroxyl, or, may be taken with R1or R2,to constitute a double bond, and Y is a methylene group if the bond to Y is a double or is a methyl group or hydrogen if the bond to Y is a single bond. 4. The method of claim 2, wherein said hypocalcemic vitamin D is a 1α-hydroxyvitamin D compound is represented by formula III: wherein A1and A2each are hydrogen or a carbon--carbon bond, thus forming a double bond between C-22 and C-23; R1and R2are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that R1and R2cannot both be an alkenyl group, or taken together with the carbon to which they are bonded, form a C3-C8cyclocarbon ring; R3is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X1is hydrogen or hydroxyl, and X2is hydrogen or hydroxyl, or, may be taken with R1or R2,to constitute a double bond. 5. The method of claim 4, wherein the compound of formula (I) is 1α,24-dihydroxyvitamin D2,1α,24-dihydroxyvitamin D4,1α,25-dihydroxyvitamin D2,1α,25-dihydroxyvitamin D4,1α-hydroxyvitamin D2or 1α-hydroxyvitamin D4. 6. A method in accordance with claim 2, wherein a dosing regimen for the hypocalcemic vitamin D compound is a daily regimen or an episodic regimen. 7. A method in accordance with claim 6, wherein the espisodic regimen is a dose once every 2 to 7 days. 8. A method in accordance with claim 6, wherein the hypocalcemic vitamin D compound is administered daily at a dose of about 10 to 100 μg/day. 9. A method in accordance with claim 6, wherein the hypocalcemic vitamin D compound is administered orally, is administered intravenously, is injected directly into a cancer site, or is regionally delivered to a cancer site. 10. A method in accordance with claim 9, wherein the hypocalcemic vitamin D compound is administered orally. 11. A method in accordance with claim 2, wherein the hypocalcemic vitamin D compound is co-administered with a cytotoxic agent. 12. A method in accordance with claim 11, wherein the cytotoxic agent is an antimetabolite, and antimicrotubule agent, an alkyating agent, a platinum agent, an anthracycline, a topoisomase inhibitor, or an antibiotic. 13. A method in accordance with claim 12, wherein the antimetabolite is 5-fluorouracil, methotrexate or fludarabine. 14. A method in accordance with claim 12, wherein the antimicrotubule agent isvincristine, vinblastine or a taxane. 15. A method in accordance with claim 11, wherein the taxane is paclitaxel or docetaxel. 16. A method in accordance with claim 12, wherein the alkylating agent is cyclophasphamide, melphalan, biochoroethylnitrosurea or hydroxyur ea. 17. A method in accordance with claim 12, wherein the platinum agent is cisplatin, carboplatin, oxaliplatin, JM-216 or CI-973. 18. A method in accordance with claim 12, wherein the anthracycline is doxrubicin or daunorubicin. 19. A method in accordance with claim 12, wherein the antibiotic is mitomycin, idarubicin, adriamycin or daunomycin. 20. A method in accordance with claim 12, wherein the topoisomerase inhibitior is etoposide or camptothecins. 21. A method in accordance with claim 12, wherein the cytotoxic agent is estramustine phosphate or prednimustine. 22. A method of treating a human to inhibit angiogenesis associated with breast cancer, colon cancer, prostate cancer, testicular cancer, pancreatic cancer, endometrial cancer, small cell and non-small cell cancer of the lung (including squamous, adneocarcinoma squamous cell of the head and neck, bladder, ovarian and cervical cancers, myeloid and lymphocyltic leukemia, lymphoma, hepatic tumors, medullary thyroid carcinoma, multiple myeloma, melanoma, retinoblastoma or sarcomas of the soft tissue and bone, comprising administering to the human an effective amount of a hypocalcemic vitamin D compound. 23. A method of claim 22, wherein said hypocalcemic vitamin D is a 1α-hydroxyvitamin D compound represented by formula III: wherein A1and A2each are hydrogen or a carbon--carbon bond, thus forming a double bond between C-22 and C-23; R1and R2are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that R1and R2cannot both be an alkenyl group, or taken together with the carbon to which they are bonded, form a C3-C8cyclocarbon ring; R3is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X1is hydrogen or hydroxyl, and X2is hydrogen or hydroxyl, or, may be taken with R1or R2,to constitute a double bond. 24. The method of claim 23, wherein said therapeutic amount is 0.01 μg/kg/day to 2.0 μg/kg/day. 25. The method of claim 23, wherein the compound of formula (I) is 1α,24-dihydroxyvitamin D2,1α,24-dihydroxyvitamin D4,1α25-dihydroxyvitaminD2,1α,25-dihydroxyvitamin D4,1α-hydroxyvitamin D2or 1α-hydroxyvitamin D4. 26. A method of treating a human to inhibit angiogenesis associated with malignant cells, comprising administering to the patient a hypocalcemic vitamin D compound and a cytotoxic agent. 27. A method in accordance with claim 26, wherein the hypocalcemic vitamin D compound is administered from 0.5 to 7 days prior to administration of the cytotoxic agent. 28. A method in accordance with claim 26, wherein the hypocalcemic vitamin D compound is administered 2 to 4 days prior to administration of the cytotoxic agent. 29. A method of claim 26, wherein said hypocalcemic vitamin D is a 1α-hydroxyvitamin D compound represented by formula III: wherein A1and A2each are hydrogen or a carbon--carbon bond, thus forming a double bond between C-22 and C-23; R1and R2are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that R1and R2cannot both be an alkenyl group, or taken together with the carbon to which they are bonded, form a C3-C8cyclocarbon ring; R3is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X1is hydrogen or hydroxyl, or, taken